Elevated WT-EGFR expression not only correlates with acquired resistance to third-generation EGFR TKIs but also participates in the maintenance of mutated KRAS activity and KRAS-driven NSCLC tumorigenesis8–11. This evidence concerns the gene EGFR and non-small cell lung carcinoma.